Three cohort studies in adults were performed during the periode from 1986 to 1989. Eight hundred and eighty-four subjects were, one or more times, immunized with inf?uenzu vaccines, and pre-and post-vaccination 
Active immunization with inactivated vaccines against influenza virus types A and B in subjects at risk of developing serious complications after influenza infection, has been advised to be repeated annually to comply with antigenic drift of the viruses and decrease of antibody levels with time. This policy, however, has been questioned by field studies in the 197Os, which suggested a decrease of protective immunity upon annually repeated vaccination'-3. Although the methods of these studies have been criticized4 and more recent studies5-7 have not confirmed these findings, the value of annual influenza vaccination still remains a subject of discussion.
Field vaccination studies are difficult to perform due to the poor predictability of influenza outbreaks, which makes power-calculations troublesome.
The most important parameters of efficacy are reduction of mortality and severe morbidity which may not occur frequently thus requiring large numbers of participants in efficacy trials. Moreover, since a beneficial effect of influenza vaccination has been established, it is no longer ethically acceptable to perform double-blind, prospective field studies in groups at risk of developing serious complications. Therefore. serological studies with hemagglutination inhibition (HI) serum antibody titres as a surrogate marker for real vaccine efficacy, are usually performed, with divergent results: sometimes a lower7.', and sometimes a higher' postvaccination serum antibody titre was observed in subjects with a vaccination history when compared to those not vaccinated before, and in other studies, post-vaccination antibody titres were not significantly affected by previous vaccinationss,'0-'7.
Here we present the results of three different cohort studies, performed in primed populations during an inter-pandemic period (19861989) with low activity of naturally occurring influenza.
Sero-response to repeated influenza vaccination: WE. F? Beyer et al. 
MATERIALS AND METHODS

Vaccinees and trials
The first two cohort studies (designated YA, young adults, and AE, ambulatory elderly) were part of open vaccination studies to comply with regulatory requirements, as described elsewhere13. Young, clinically healthy adults were recruited from medical schools and other teaching institutions in The Netherlands. Ambulatory elderly with (70%) or without (30%) agerelated chronic diseases, were recruited from a general geriatric outpatients' department in Switzerland. Before intake, previous vaccinations against influenza were documented. In total, 237 young adult and 221 elderly subjects were vaccinated once or more times in the period from 1986 to 1989, respectively. During the study period, no cases of influenza-like illness (ILI) were reported by the vaccinees.
The third cohort study (designated RE. resident elderly) took place in a Dutch rural nursing home with 275 beds (135 for somatic patients and 140 for psychogeriatric patients). Before 1986, only a few patients received influenza vaccine on their own request. But. when in January/February 1986 a large influenza A-H3N2 epidemic affected 103 of the patients (37%)14, general vaccinations were performed every year since autumn 1986. The annual vaccination rate in the nursing home varied between 7 1 and 8 l%, involving 426 patients who were vaccinated once or more times between 1986 and 1989. Most of these subjects (97%) were older than 60 years of age at the moment of first vaccination. The vaccination history of new entries could not always be traced back in patients with dementia. In March 1989 a small epidemic of IL1 occurred in 19 patients (influenza B serologically confirmed in seven patients).
All volunteers (or in case of dementia, their relatives) gave informed consent to participate in the trials. For the cohort studies YA and AE, Medical Ethical Committee approval was obtained.
For this study, vaccinees were selected according to the following post-hoc criteria:
(1) Age: In cohort studies AE and RE only subjects born in 1927 or earlier were included; in cohort study YA only subjects born after 1927 were included. Complete serology: Subjects with incomplete either pre-or post-vaccination sera due to lack of compliance or organization mistakes, or subjects with less than 15 days between pre-and post-vaccination serum, or subjects with missing titres for either serum or either vaccine component due to laboratory limitations, were excluded from the actual trial (but not necessarily from the following trials).
Vaccine preparations and doses
Inactivated influenza vaccines (Influvac whole-virus vaccine, Influvac subunit vaccine; Solvay-Duphar BV, Weesp, The Netherlands) contained strains of influenza A-H3N2, A-HlNl and B, according to the annual recommendations of the World Health Organization. As shown in Table 1 , the A-HlNl component remained unchanged for most years while the A-H3N2 and B components were replaced by new variants every 1 or 2 years. The influenza vaccine type was whole-virus for cohort study RE, and subunit for cohort studies YA and AE. Vaccine doses varied between 10 and 15 ,ug HA per strain, except for two dose-response trials in 1986. Vaccines were administered intramuscularly or deep subcutaneously.
Serological methods
Serum specimens were collected prior to vaccination (pre-vaccination serum) and again after at least 15 days Sero-response to repeated influenza vaccination: kV. E.!? Beyer et al. (post-vaccination serum). Samples were stored frozen prior to laboratory determinations of homologous hemagglutination-inhibition (HI) antibody titres. All sera of a trial were titrated simultaneously and in duplicate. Cohort studies YA and AE were titrated in the laboratory of Solvay-Duphar, with a test-antigen concentration of 4-8 hemagglutination units (HAU)", without ether-treatment of influenza B test-antigen. With this method, protection is supposed to be associated with a titre of 240 (influenza A) and 220 (influenza B). Negative sera (no inhibition in a 1:8 dilution) were arbitrarily recorded as 4 for calculations. Cohort study RE was titrated at the National Influenza Centre, by a similar method, but with a lower test-antigen concentration of 3 HAU16, and with ether-treatment of influenza B test-antigen"; this method produced high absolute titres and was described as being associated with a protection threshold of 2 100 (influenza A)18 and 2200 (influenza B)19. Negative sera (no inhibition in a 1:9 dilution) were arbitrarily recorded as 5. Titre values were transformed to decadic logarithms.
Association of the "protection thresholds" (40/20 or 100/200) with real protection is controversial. For convenience, we called subjects surpassing the appropriate titre thresholds "protected subjects", rather than "subjects with high antibody titre".
Statistical methods
As titrations were performed separately per trial, no comparisons could be made between, but only within trials. Per trial and per vaccine component, pre-and post-vaccination geometric mean titres (pre-GMT, post-GMT), and pre-and post-vaccination proportions of protected subjects (pre-PR, post-PR) were calculated for subgroups with previous vaccination (effect groups) and without previous vaccination (control groups).
Per trial and per vaccine component, the effect of previous vaccination was estimated by measuring the differences between effect and control groups. Three effect measures were calculated:
Effect size (Es) (according to Dawson-Saunders et ul.'"), defined as:
where GMT, and GMT, represent the geometric mean titres of the control and effect groups, respectively, and S.D.rooled is the pooled standard deviation.
Logarithm of odds ratio (O.R.), defined as:
ln0. R. =ln(A+O.5)*(D+O.5)l((B+0.5)*(C+0.5)).
where A and C are the numbers of protected subjects in the control and effect groups, respectively, and B and D are the numbers of not protected subjects in control and effect group, respectively. Rate difference (RD), defined as:
where PR, and PR, are the proportions of protected subjects in the control and effect groups, respectively.
ES-, In 0. R.-and RD-values are 0 in case of no difference between effect and control group (i.e. no effect of previous vaccination); they are positive in case of higher titres or percentage of protection in the group with previous vaccinations, compared to the control group, and vice versa. The calculation of 95% confidence intervals allows to define the significance of the effect measures.
Per (sub)type, effect measures from all trials were pooled by a one-step technique of meta-analysis as described previously (Yusuf-Peto modified CochranMantel-Haenzel method") resulting in pooled values for influenza A-H3N2, A-HlNI and B, respectively. The validity of the pooling procedure was tested by a xz-test for homogeneity between trials, according to Breslow and Day".
Per trial and per vaccine component, post-GMT were subjected to linear regression with status of previous vaccinations (i.e. 0 for control groups, 1 for effect groups) as independent variable. In a first model of linear regression also other factors were included as independent variables: pre-vaccination titre, year of birth, gender, days between vaccination and drawing 01 post-vaccination blood specimen, number of previous vaccinations (one to three times), underlying diseases (for cohort studies AE and RE), vaccine dosages in 1986 (for cohort studies YA and RE), and clinically or virologically confirmed IL1 in January/February 1986 and March 1989 (for cohort study RE). In a consecutive model, only those factors were included which significantly contributed to post-vaccination GMT in the first model. In a similar procedure, post-vaccination percentages of protection were subjected to logistic regression.
For all statistical procedures, a P-value of 0.05 or less was considered to indicate statistical significance. Calculations were done on a personal computer using a statistical software package (SPSS/PC+4.0; Microsoft Corporation, Redmond/Washington, USA).
RESULTS
Final numbers of vaccinees with complete serology
As shown in Table 2 , in three cohort studies 1715 vaccinations were performed, involving 884 subjects who were vaccinated once or more times during the period from 1986 to 1989. After applying the post-hoc selection criteria described in Materials and Methods, 1119 paired sera of 681 subjects entered the analysis: in cohort study YA, 181 subjects with a mean year of birth of 1963 (range 1942-1969 ) and a percentage of male subjects of 44, in cohort study AE, 198 subjects with a mean year of birth of 1913 (1892-1927) and 47% male subjects, and in cohort study RE, 298 subjects with a mean year of birth of 1906 (1889-1927) and 27% male subjects. Table 2 also presents subjects per trial, according to vaccinations.
the numbers of selected the number of previous
Pre-and post-vaccination titres
Figure I presents pre-and post-vaccination GMTvalues and proportions of protected subjects according to influenza (sub)types, trials and status of previous vaccination. Per trial, pre-GMT and pre-PR were, in YA  1986  143  3  140  1987  130  5  7  118  25  93  1988  149  4  2  143  63  18  62  AE  1986  63  10  53  1987  116  10  3  103  40  63  1988  139  10  3  126  54  28  44  1989  113  6  6  101  41  0  22  38  RE  1986  234  7  4  223  1987  209  6  4  z5  194  59  135  1988  196  5  7  159  40  25  94  1989  223  10  16  22  175  64  18 Figure 1 Pre-and post-vaccination mean titres, and proportions of protected subjects, according to trial and status of previous vaccination. (1.1) shows the geometric mean titres (GMT), (1.2) the proportion of protected subjects (% PROT). The whole bar represents the post-vaccination titre (1 .l), or the post-vaccination proportion of protected subjects (1.2); the lower part of the bar represents the pre-vaccination titre, or the pre-vaccination proportion of protected subjects. T, upper 95% confidence limit of post-vaccination titre (1 .l); PREVAC, status of previous vaccination (0, control group-not previously vaccinated; 1, effect group-previously vaccinated)
virtually all cases, higher in previously vaccinated groups than in the control groups, regardless of the age-class and the antigenic resemblance of the consecutive virus strains per (sub)type. Post-GMT and post-PR were much less uniform: In previously vaccinated groups, in some cases these variables were higher, in other cases lower than the respective control groups. For the influenza A strains, no large differences could be detected in most cases. For influenza B, however, there appeared a general tendency to lower post-GMT and post-PR in groups with previous vaccination. Figure 2 showing three different effect measures according to trial and (sub)type, reveals that the generally positive effect of previous vaccination on prevaccination titres was significant in the majority of trials. Only one trial (RE 1989 for influenza B) had an insignificantly lower percentage of protected subjects previously vaccinated compared to the control group. In contrast, a clear-cut effect of previous vaccination on the post-vaccination status was not present: most values, either positive or negative, were not significantly Pm-vaccination titre all pooled effect measures were significantly positive. The average additional effect of previous vaccination on pre-vaccination proportion of protected subjects ( Figure  3c ) was +22.3% for A-H3N2, +15.8% for A-HlNl and +4.2% for B. In contrast, the pooled effect measures of post-vaccination titres were positive only for A-H3N2 (pooled In O.R. and RD even significantly so), negative but very close to zero for A-H lN1, and significantly negative for B. In other words, on average previous vaccination is associated with higher post-vaccination titres for A-H3N2 vaccine components, compared with not previously vaccinated subjects, and with lower titres for B components. There is no such effect for the A-HlNl component. The average increase of the postvaccination proportion of protected subjects, due to previous vaccination, was +9.4% (95% CI: +5.3 to +13.6%), the average decrease for B was -10.6% (-16.5to -4.8%),andforA-HlNl -2.1%(-8.1%to +3.9%) (Figure 3c ).
Effect measures
Variables influencing post-vaccination titres
Per trial and (sub)type, and in part within relevant subpopulations, post-vaccination titres and postvaccination protection were subjected to linear regression and logistic regression, respectively, including a number of independent variables. Year of birth within the given range of the cohort study (2 1928 for YA, cl928 for AE and RE), gender, days between vaccination and drawing of post-vaccination blood specimen, number of previous vaccinations, underlying diseases (for cohort studies AE and RE), vaccine dosages in 1986 (for cohort study YA and RE), and clinically or virologically confirmed illness in January/February 1986 and March 1989 (for cohort study RE) did not show a significant contribution to post-vaccination titres. In all comparisons, the pre-vaccination titre was the strongest predictor of the post-vaccination status. In most com-parisons, also status of previous vaccination contributed significantly to post-vaccination titres.
Linear regression on post-vaccination titres was repeated with only pre-vaccination titres and status of previous vaccination as independent factors. The resulting regression coefficients for both factors are shown in Table 3 . Ail regression coefficients for pre-vaccination titre were significantly 0, confirming the well-known strong positive linear relationship between pre-and post-vaccination titres. Regression coefficients for the status of previous vaccination, all but one, were negative. The addition of an interaction term (the product of pre-vaccination titre and status of previous vaccinations) did not improve the model.
DISCUSSION
The first main result of our paper concerns the prevaccination titres: they are generally higher in effect groups (previously vaccinated) than in control groups (not previously vaccinated). This finding is biologically plausible (persistence of vaccine-induced antibody) and has been previously described in other papers5.7-12.'7.
Our second main finding, on post-vaccination titres, is not clear-cut: post-vaccination titres of effect groups can be higher than, equal to, or lower than those in control groups. When pooling the effect measures of all trials according to (sub)type, we saw a tendency to higher post-vaccination titres for the A-H3N2 vaccine components, the opposite for B components and virtually no effect for A-HlNl. This also implies that the sequence of consecutive vaccine-strains in the period 19861989 had obviously no influence. The (sub)type difference of effect measures is not reflected by the fact that both A-H3N2 and B vaccine components changed more frequently than the A-HI Nl component.
In this paper, we examined three different study populations. Age differences could have affected the 1987 1988 1987 1988 1989 1988 1989 1987 1988 1987 1988 1989 1987 1988 1989 1987 1988 1987 1988 1989 1987 1988 1989 23,24), and the which remained in the vaccine composition during the influenza-specific phenomenon of "original antigenic sin"2s.
whole study period, while the A-H3N2 and B com- Figure 2 reveals, however, that there are no real ponents were replaced by new strains every 1 or 2 years. differences between the effect measures of the cohort Our approach, a comparison of effect and control studies YA (young adults, most of whom born after groups strictly per trial, allowed to ignore the 1957) and AE (ambulatory elderly, born in 1927 or between-trial differences of A-H3N2 and B components, earlier). In particular this was true for influenza and the differences due to titration methods. A possible A-HlNl, the subtype of which the seroresponse is statistical inferiority, compared with individual followusually strongest affected by the original antigenic sin as it had disappeared in 1957 and reappeared in 197726. up, may have been compensated by the large number of data (1119 paired sera). Other differences between our study populations concern the influenza vaccine types (subunit vaccine in YA and AE, whole-virus vaccine in RE), and the epidemiological characteristics: RE consisted of a semiclosed community (nursing home), while the vaccinees of AE and YA belonged to the general, epidemiologically open, population. Natural influenza, like the A-H3N2 epidemic in RE in 1986, has a much stronger impact in semi-closed communities which may modulate the response on vaccination in the following years. However, we did not find, by regression analysis, any such influence in our data. Another difference may be that the groups of previously not-vaccinated subjects were better defined in AE and YA than in RE where subjects with previous vaccination outside the nursing home could not always be identified because of the high proportion of dementia. We believe that the combined influence of all these population characteristics did not seriously affect our outcome measures, as can be derived from the only small inter-trial variation (Figure 2) . Serum titrations were done per trial, on different points of time, in two different laboratories, and with different protocols of the HI test. This approach did not allow for comparisons between trials, and specially not for the follow-up of those individuals who had participated during the whole study period. Such an individual To compare our finding on post-vaccination titres with the international literature, we identified nine papers wherein rate differences could be calculated. Table 4 shows the results of, in total, 34 comparisons. In 26 comparisons, rate differences were not significantly different from zero (i.e. no effect of previous vaccination). In two comparisons, rate differences were significantly higher in the effect groups (one time A-H3N2, one time A-HlNl), and in six comparisons rate differences were significantly lower (one time A-H3N2, two times A-HlNl, three times B). Of special interest were the studies of Govaert et aZ. ' and Glathe et a1.9 . Both studies were performed in the same year (i.e. identical strains) with the same vaccine type (split-virus). Nevertheless, Govaert et We saw in our data that an individual postvaccination titre is strongly dependent on the prevaccination titre and, inversely, on the status of previous vaccination. The linear relationship between pre-and post-vaccination titre is well known29. The inverse 906 -18.4 (-27.4--9 (Hl Nl) and B/Panama/45/90, in young and elderly adults; they did not present data on previous vaccinations but stated that "subgroup analysis showed that previous vaccination had no effect on the response to the different strains measured in the study" (p. 1059). Table 2 of the paper, with "group 1" as effect group and "group 2" as control group in 1991, and "group 1" and "group 2" as pooled effect group and "group 3" as control group in 1992. Data for A/Taiwan/l/86 (Hl Nl) and B/Panama/45/90 were not given. Calculations are based on data for AIFinland/l64/91 (HlNl) and B/Yamagata/l6/88 relationship between status of previous vaccination and post-vaccination titre has already been seen by Peters et al. ' and Pyhlla et aE. 28 At a given pre-vaccination titre, the post-vaccination titre can be expected to be lower in previously vaccinated subjects than in not previously vaccinated subjects. Thus, natural antibody, caused by previous infections, has a larger potential to form high post-vaccination titres, than the same amount of vaccine-induced antibody3'. The biological interpretation of the inverse relationship between status of previous vaccination and postvaccination titre is troublesome. The phenomenon could be described as a "negative booster effect of previous vaccinations" suggesting an active immunological feed-back mechanism which inhibits the production of additional post-vaccination antibody. It has also been pointed out that natural and vaccine-induced antibody may differ in their IgA-and IgG-subclass composition or their ratio of strain-specific and crossreacting components which are not differentiated by the HI-test. It is also possible that the inverse relationship is a pure "mathematical artifact" in the sense that postvaccination antibody may reach a plateau after first vaccination which can not be exceeded by repeated vaccinations. Since at the same time pre-vaccination titre is higher after repeated vaccination, a negative coefficient for repeated vaccinations occurs in the regression equation which has no biological meaning at all.
It should be underlined that our data were based on the HI-titre, i.e. a surrogate marker for real vaccine efficacy. In high concentrations, the HI-titre is a good marker, or in other words: a vaccine which induces high HI-titres, is undoubtedly a highly effective means to prevent serious influenza illness. On the other side, a vaccine, which induces low HI-titre should not automatically be regarded as inferior if it stimulates other immunological measures which are also protective even without high HI-titres. Therefore, our finding that, specially in cohort studies AE and YA, post-vaccination HI-antibody decreased after annually repeated vaccination for the influenza B component, does not necessarily mean that real protection against natural influenza B evenly decreased in these groups. In studies which recorded natural infections in groups with and without repeated vaccinations, subjects with previous vaccination showed an equal or even greater protection against natural influenza compared to those without'-'.
Thus, while annually repeated influenza vaccination has probably no negative clinical impact, it should always be included as an independent factor in serological vaccination studies.
